Topical Clindamycin 1 % for Mild‑to‑Moderate Hidradenitis Suppurativa

Indications and Patient Selection

The American Academy of Dermatology (AAD) recommends topical clindamycin 1 % solution for patients with Hurley stage I or II disease (mild‑to‑moderate HS). 1
It is appropriate when lesions are predominantly pustular rather than deep nodules or abscesses. 1
Pediatric patients aged 9 years and older with mild disease may be treated with this regimen. 5
In pregnant patients, topical clindamycin may be used as a conditional recommendation when a topical antibiotic is required. 5

Use the 1 % clindamycin solution (the only topical formulation studied in HS). 1
Apply a thin film twice daily to all affected areas for 12 weeks, as established by a pivotal randomized controlled trial. 1

In RCTs, topical clindamycin 1 % significantly reduces the number of pustules but shows minimal to no effect on inflammatory nodules and abscesses. 1
Patients report improved self‑assessment of disease severity after treatment. 1

Co‑application of benzoyl peroxide with clindamycin is mandatory to reduce the emergence of Staphylococcus aureus resistance in HS patients. 1
Adjunctive antiseptic washes (e.g., chlorhexidine, benzoyl peroxide, or zinc pyrithione) may be used to further limit bacterial colonisation. 1

Topical clindamycin alone is insufficient for inflammatory nodules, abscesses, or Hurley stage III disease; systemic therapy is required. 1
For moderate‑to‑severe HS (≥ 5 inflammatory nodules), oral clindamycin 300 mg + rifampin 300 mg twice daily for 8–12 weeks yields a 71‑93 % clinical response rate. 1

Resorcinol 15 % cream applied twice daily during flares and daily between flares reduces pain and shortens abscess duration, though irritant dermatitis is common. 1
Intralesional triamcinolone (10 mg/mL, 0.2–2.0 mL per lesion) provides rapid pain relief within 1 day for acute inflammatory lesions. 1

Do not use topical clindamycin for nodules or abscesses, as it lacks efficacy for these lesion types. 1
Never prescribe clindamycin without concurrent benzoyl peroxide, as monotherapy promotes antibiotic resistance. 1
Reassess disease severity after 12 weeks; discontinue or modify therapy if lesions persist or worsen, and consider systemic options. 1